Home > Boards > US Listed > Biotechs > Eloxx Pharmaceuticals Inc. (ELOX)

The company will make two presentations on SNS01T

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Eloxx Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020 GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant GlobeNewswire Inc. - 9/14/2020 10:06:20 AM
Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Confer... GlobeNewswire Inc. - 8/26/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2020 7:55:55 AM
Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 P... GlobeNewswire Inc. - 8/12/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 8:16:56 AM
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update GlobeNewswire Inc. - 8/6/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 7:51:30 AM
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis GlobeNewswire Inc. - 8/4/2020 7:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:05 PM
Eloxx Pharmaceuticals to Present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13th, 2020 GlobeNewswire Inc. - 7/28/2020 12:33:50 PM
Eloxx Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020 GlobeNewswire Inc. - 7/21/2020 2:17:29 PM
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics GlobeNewswire Inc. - 7/15/2020 1:08:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2020 4:47:30 PM
Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily ... GlobeNewswire Inc. - 6/17/2020 4:01:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/26/2020 3:04:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:12:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:06 PM
investora2z   Tuesday, 11/12/13 09:36:13 AM
Re: None
Post # of 773 
The company will make two presentations on SNS01T for blood-borne cancer care at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 7-10. It will provide an update on the current results of the Phase 1b/2a trial. It will also make an oral presentation of new results with SNS01-T in non-clinical studies. The abstracts to be presented include “Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma" and "SNS01-T Exhibits Significant Anti-Tumoral Activity In Models Of Multiple Myeloma and Non-Hodgkins B Cell Lymphoma and Induces Cell Death In Malignant But Not Normal B Cells". The company has been in the news recently mainly because of the expected declaration of the cohort 3 trials. The update in the first week of December and detailed results could be an important trigger for the stock. The stock has shown some signs of a rebound, and it will show strength in case the update / results come in better than expected on the safety & efficacy fronts. The results so far have been encouraging, but they need to be confirmed at higher dosages. Tolerance at higher doses is critical to the usability of the drug. Some analysts have pointed out that the stock is undervalued compared to other development stage companies. The Chairman and one Director has put in money at $26 which is more than 5 times the current market price. Chairman Waksal would not have put in money in the company without being confident about the prospects of SNS01T. The update in early December could provide a trigger for the short term. Long term movement will depend on the company's ability to find funds to support the further trials, and, obviously, the results.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences